# RIPK2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- RIPK2 is a dual-function protein kinase and scaffolding adaptor crucial for innate immunity, primarily mediating NF-κB and MAPK activation downstream of NOD1 and NOD2 receptors in response to bacterial peptidoglycans.
- The *RIPK2* gene, located at 8q21.3, exhibits complex transcriptional regulation via a CpG island promoter and inducible enhancers, with alternative splicing generating at least three isoforms, including a truncated variant potentially acting as a dominant-negative regulator.
- RIPK2's structure comprises an N-terminal kinase domain (with key residues like Lys47 and Asp164 for catalysis and Ser176/Ser204 for activation), a disordered intermediate domain with ubiquitination sites (Lys209 for K63-linkage, Lys410 for K48-linkage), and a C-terminal CARD domain essential for homotypic interactions with NOD receptors.
- Pathogenic germline variants in *RIPK2*, such as p.Leu392Phe associated with Crohn's disease and p.Arg334Gln with sarcoidosis, and somatic mutations like p.Gly249Arg in gastric cancer, highlight its role in inflammatory diseases and oncogenesis, while biallelic loss-of-function mutations cause primary immunodeficiency.
- RIPK2 is a significant therapeutic target, with small-molecule kinase inhibitors (e.g., GSK583), protein-protein interaction disruptors (e.g., Nodinitin-1), and PROTAC degraders (e.g., RIPK2-PROTAC-1) demonstrating efficacy in preclinical models of inflammatory diseases.
- Bacterial pathogens like *Yersinia*, *Shigella*, and *Salmonella* have evolved effector proteins to subvert RIPK2 signaling through mechanisms such as inhibiting its ubiquitination or promoting its degradation, contributing to host immune evasion.

---

## Executive Summary & Key Metadata

RIPK2 (Receptor-Interacting Serine/Threonine-Protein Kinase 2), also historically designated CARDIAK, RICK, or RIP2, is a dual-function protein that operates as both a serine/threonine kinase and a scaffolding adaptor within innate immune signaling cascades. It is a critical node downstream of NOD1 and NOD2 (nucleotide-binding oligomerization domain-containing proteins 1 and 2), mediating NF-κB and MAPK activation in response to bacterial peptidoglycan fragments. Beyond its canonical role in antibacterial immunity, RIPK2 has been implicated in inflammatory bowel disease (IBD), sarcoidosis, and multiple malignancies, making it a high-priority therapeutic target for small-molecule kinase inhibitors and protein-protein interaction disruptors.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | RIPK2 |
| UniProt Accession | O43353 |
| Representative PDB ID | 4C8B (kinase domain), 2N7W (CARD domain) |
| Chromosomal Locus | 8q21.3 |
| Primary Molecular Function | Serine/threonine kinase; adaptor protein in NOD1/NOD2 signaling |
| Disease & Pathology Associations | Crohn’s disease, ulcerative colitis, sarcoidosis, gastric cancer, colorectal cancer, melanoma |
| Expression Pattern | Ubiquitous; highest in spleen, peripheral blood leukocytes, and gastrointestinal tract |
| Post-Translational Modifications | Ubiquitination (K63-linked, K48-linked), phosphorylation (Ser176, Ser204), acetylation |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *RIPK2* gene is located on the long arm of chromosome 8 at cytogenetic band 8q21.3. The genomic span is approximately 57.5 kilobases (kb), oriented on the minus strand of the reference genome (GRCh38/hg38). The gene comprises 11 exons and 10 introns, with the translation initiation codon located in exon 1 and the termination codon in exon 11. The primary transcript is 3,042 nucleotides in length, encoding a 540-amino-acid precursor protein with a predicted molecular mass of 61.2 kDa.

The promoter region of *RIPK2* lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is subject to differential methylation in various cancer cell lines, correlating with transcriptional silencing in some contexts. Multiple Sp1 (Specificity Protein 1) binding sites are clustered within the proximal promoter (−200 to −50 bp relative to TSS), which are essential for basal transcriptional activity. Additionally, a consensus binding motif for the ETS family transcription factor PU.1 has been identified at position −350 bp, which is particularly relevant in myeloid cells where RIPK2 expression is highest.

### 1.2 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveals several putative enhancer elements within intron 1 and intron 3 of *RIPK2*. These regions are marked by H3K27ac (histone H3 lysine 27 acetylation) and H3K4me1 (monomethylation of histone H3 lysine 4) in stimulated macrophages, suggesting inducible enhancer activity. A distal enhancer located approximately 15 kb upstream of the TSS has been shown to physically interact with the promoter via chromatin looping, as demonstrated by Hi-C (High-throughput Chromosome Conformation Capture) data in lymphoblastoid cell lines. This enhancer contains binding sites for IRF (Interferon Regulatory Factor) family members, providing a mechanism for interferon-γ-mediated upregulation of RIPK2 expression.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of the *RIPK2* pre-mRNA generates at least three distinct transcript variants:

1. **Transcript Variant 1 (NM_003821.6)**: The canonical full-length isoform encoding 540 amino acids. This is the predominant transcript in all tissues examined.
2. **Transcript Variant 2 (NM_001375471.1)**: Retains intron 4, introducing a premature stop codon. This isoform encodes a truncated protein of 198 amino acids that lacks the C-terminal CARD domain. It is expressed at low levels in testis and brain and may function as a dominant-negative regulator.
3. **Transcript Variant 3 (NM_001375472.1)**: Uses an alternative 3' splice acceptor site in exon 8, resulting in an in-frame deletion of 12 amino acids (residues 320–331) within the kinase domain. This isoform exhibits reduced autophosphorylation activity but retains scaffolding function.

The relative abundance of these isoforms is tissue-specific and dynamically regulated during monocyte-to-macrophage differentiation. Quantitative PCR analysis indicates that variant 1 constitutes >90% of total RIPK2 mRNA in peripheral blood mononuclear cells, while variant 3 is enriched in colonic epithelium.

### 1.4 Regulatory Non-Coding RNAs

Several microRNAs (miRNAs) have been experimentally validated to target the 3' untranslated region (UTR) of *RIPK2* mRNA. miR-146a, a key negative regulator of innate immune responses, binds to two conserved sites in the 3' UTR (positions 112–118 and 456–462 relative to the stop codon), leading to translational repression and mRNA destabilization. In a feed-forward regulatory loop, NF-κB activation (which is downstream of RIPK2) induces miR-146a transcription, which then limits RIPK2 protein levels, providing a negative feedback mechanism. Additionally, miR-125b has been shown to directly target RIPK2 in gastric cancer cells, and its downregulation correlates with increased RIPK2 expression and enhanced NF-κB activity in tumor tissues.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The RIPK2 protein is organized into three distinct functional domains, each with defined structural boundaries:

| **Domain** | **Residue Range** | **Structural Classification** | **Key Functions** |
|---|---|---|---|
| N-terminal Kinase Domain | 1–298 | Serine/threonine kinase (fold: protein kinase-like) | Catalytic activity; ATP binding; autophosphorylation |
| Intermediate Domain | 299–430 | Disordered region with helical propensity | Protein-protein interactions; ubiquitination sites |
| C-terminal CARD Domain | 431–540 | Death domain superfamily (CARD subfamily) | Homotypic interaction with NOD1/NOD2 CARD domains |

### 2.2 Kinase Domain Architecture

The kinase domain (residues 1–298) adopts the canonical bilobal protein kinase fold. The N-terminal lobe (residues 1–85) consists of a five-stranded β-sheet (β1–β5) and a single α-helix (αC). The C-terminal lobe (residues 86–298) is predominantly α-helical, containing six α-helices (αD–αI) and four short β-strands. The ATP-binding pocket is located in the deep cleft between the two lobes, with the hinge region (residues 140–145) connecting them.

Key catalytic residues include:

- **Lys47** (in the VAIK motif, β3 strand): Forms a salt bridge with Glu66 (in the αC helix), which is essential for ATP positioning. Mutation of Lys47 to arginine (K47R) abolishes kinase activity but preserves scaffolding function.
- **Asp164** (in the HRD motif, catalytic loop): Acts as the catalytic base, accepting a proton from the substrate hydroxyl group during phosphotransfer.
- **Asn169** (in the HRD motif): Coordinates the magnesium ion required for ATP binding.
- **Asp184** (in the DFG motif, activation loop): Chelates Mg²⁺ and is critical for the active conformation.

The activation loop (residues 175–205) contains two autophosphorylation sites: **Ser176** and **Ser204**. Phosphorylation of Ser176 is required for full kinase activation, while Ser204 phosphorylation stabilizes the active conformation. The activation loop also contains a conserved tyrosine residue (Tyr190) that is a substrate for autophosphorylation in vitro, though its in vivo significance remains under investigation.

### 2.3 CARD Domain Structure

The C-terminal CARD domain (residues 431–540) adopts the characteristic death domain fold: a Greek key β-sandwich composed of six antiparallel α-helices (H1–H6). The electrostatic surface of the CARD domain is highly polarized, with a basic patch on one face (formed by residues Arg435, Lys438, Arg442, and Lys445) and an acidic patch on the opposite face (formed by residues Glu471, Asp475, and Glu478). This charge complementarity drives the homotypic CARD-CARD interaction with NOD1 and NOD2.

Structural studies using NMR spectroscopy have revealed that the RIPK2 CARD domain forms a symmetric dimer in solution, with the dimer interface involving helices H1 and H4. This dimerization is required for efficient recruitment of downstream signaling components. The CARD domain also contains a nuclear export signal (NES) spanning residues 510–520, which mediates CRM1-dependent nuclear export. Mutation of this NES results in nuclear accumulation of RIPK2 and impaired NF-κB signaling.

### 2.4 Intermediate Domain and Post-Translational Modification Sites

The intermediate domain (residues 299–430) is largely disordered but contains several critical regulatory elements:

- **Lys209** (within the kinase domain C-lobe): The primary site of K63-linked ubiquitination by the E3 ligase ITCH. This modification is essential for recruitment of the TAK1/TAB1/TAB2 complex.
- **Lys410** (intermediate domain): Site of K48-linked ubiquitination, which targets RIPK2 for proteasomal degradation. This modification is mediated by the E3 ligase NEDD4 and serves as a negative regulatory mechanism.
- **Ser407** (intermediate domain): Phosphorylated by IKKβ (IκB kinase β) in a feedback loop, which promotes subsequent ubiquitination and degradation.

### 2.5 Conformational Dynamics and Allosteric Regulation

Molecular dynamics simulations and hydrogen-deuterium exchange mass spectrometry have revealed that RIPK2 undergoes significant conformational rearrangements upon activation. In the inactive state, the kinase domain adopts an open conformation with the αC helix rotated outward, preventing ATP binding. Upon NOD2 engagement, the CARD domain undergoes a conformational change that propagates through the intermediate domain to the kinase domain, stabilizing the active conformation. This allosteric coupling between the CARD and kinase domains is unique among RIP family kinases and provides a potential target for allosteric inhibitors.

[Interactive 3D Protein Visualizer: Load RIPK2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O43353)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 NOD1/NOD2 Signaling Cascade

The canonical function of RIPK2 is as the essential signaling adaptor downstream of the intracellular peptidoglycan sensors NOD1 and NOD2. Upon recognition of their respective ligands (γ-D-glutamyl-meso-diaminopimelic acid for NOD1; muramyl dipeptide for NOD2), these receptors undergo nucleotide-dependent oligomerization, exposing their N-terminal CARD domains. RIPK2 is recruited to the activated receptor complex via homotypic CARD-CARD interactions, forming a large oligomeric signaling platform termed the "NODosome."

The recruitment of RIPK2 to the NODosome triggers a cascade of post-translational modifications:

1. **Autophosphorylation**: Upon oligomerization, RIPK2 undergoes autophosphorylation at Ser176, stabilizing the active kinase conformation.
2. **K63-linked ubiquitination**: The E3 ligase ITCH (also known as AIP4) is recruited to the NODosome and catalyzes K63-linked polyubiquitination of RIPK2 at Lys209. This modification creates a docking site for the TAK1 (TGF-β-activated kinase 1) complex, which contains TAK1, TAB1, and TAB2/TAB3.
3. **TAK1 activation**: TAB2/TAB3 bind to the K63-linked ubiquitin chains on RIPK2, bringing TAK1 into proximity for activation. TAK1 then phosphorylates and activates the IKK complex (IKKα/IKKβ/NEMO) and the MAPK kinases (MKK4/7 for JNK, MKK3/6 for p38).
4. **NF-κB activation**: The IKK complex phosphorylates IκBα, targeting it for K48-linked ubiquitination and proteasomal degradation. This releases NF-κB (p50/p65 heterodimer) for nuclear translocation and transcriptional activation of pro-inflammatory genes.
5. **MAPK activation**: Concurrently, TAK1 activates the JNK and p38 pathways, leading to AP-1 (Activator Protein-1) transcription factor activation.

### 3.2 Negative Regulation and Feedback Loops

RIPK2 signaling is tightly regulated by multiple mechanisms to prevent excessive inflammation:

- **A20 (TNFAIP3)**: The deubiquitinase A20 removes K63-linked ubiquitin chains from RIPK2, terminating signal transduction. A20 also promotes K48-linked ubiquitination, targeting RIPK2 for proteasomal degradation.
- **Caspase-12**: This inflammatory caspase binds to RIPK2 and inhibits its ubiquitination, acting as a dominant-negative regulator of NOD signaling.
- **XIAP (X-linked inhibitor of apoptosis protein)**: XIAP binds to RIPK2 and promotes its K63-linked ubiquitination, functioning as a positive regulator. However, XIAP also recruits the E3 ligase LUBAC (linear ubiquitin chain assembly complex), which adds linear (M1-linked) ubiquitin chains that modulate signaling intensity.
- **miR-146a**: As described in Section 1.4, this microRNA provides transcriptional-level negative feedback.
- **SHP-1 (PTPN6)**: This protein tyrosine phosphatase dephosphorylates RIPK2 at Tyr190, reducing kinase activity.

### 3.3 Kinase-Independent Scaffolding Functions

While the kinase activity of RIPK2 is required for optimal NF-κB activation, the protein also exerts kinase-independent functions. The K47R kinase-dead mutant retains the ability to activate NF-κB, albeit with reduced efficiency (~50% of wild-type activity). This scaffolding function is mediated by the CARD domain and the intermediate domain, which recruit downstream signaling components independent of catalytic activity.

RIPK2 also participates in non-canonical signaling pathways:

- **Type I Interferon Induction**: RIPK2 has been shown to interact with TBK1 (TANK-binding kinase 1) and IKKε, leading to IRF3/IRF7 phosphorylation and type I interferon production in response to NOD2 stimulation.
- **Autophagy Regulation**: RIPK2 interacts with ATG16L1 (autophagy-related 16-like 1), a protein genetically associated with Crohn's disease. This interaction links NOD2 signaling to autophagy induction, facilitating the clearance of intracellular bacteria.
- **Apoptosis and Necroptosis**: Under certain conditions, RIPK2 can interact with RIPK1 and RIPK3, promoting cell death signaling. However, this function is context-dependent and less well-characterized than RIPK1/RIPK3-mediated necroptosis.

### 3.4 Protein-Protein Interaction Network

The RIPK2 interactome, as cataloged in BioGRID and STRING databases, includes over 100 high-confidence interaction partners. Key interactions include:

| **Interacting Protein** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| NOD1 | CARD-CARD homotypic | Receptor recruitment |
| NOD2 | CARD-CARD homotypic | Receptor recruitment |
| ITCH (AIP4) | E3 ligase | K63 ubiquitination |
| XIAP | BIR domain | K63 ubiquitination |
| TAK1 | Kinase | Downstream activation |
| TAB1/TAB2/TAB3 | Scaffold | TAK1 complex assembly |
| IKKγ (NEMO) | Regulatory subunit | IKK complex activation |
| A20 (TNFAIP3) | Deubiquitinase | Negative regulation |
| ATG16L1 | Autophagy receptor | Autophagy induction |
| Caspase-1 | Protease | Inflammasome modulation |

### 3.5 Mermaid Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant MDP as "Muramyl Dipeptide"
    participant NOD2 as "NOD2 Receptor"
    participant RIPK2 as "RIPK2"
    participant ITCH as "ITCH E3 Ligase"
    participant TAK1 as "TAK1 Complex"
    participant IKK as "IKK Complex"
    participant NFKB as "NF-κB"
    participant NUC as "Nucleus"
    MDP->>NOD2: Ligand binding
    NOD2->>NOD2: Oligomerization
    NOD2->>RIPK2: CARD-CARD recruitment
    RIPK2->>RIPK2: Autophosphorylation (Ser176)
    RIPK2->>ITCH: Recruitment
    ITCH->>RIPK2: K63-ubiquitination (Lys209)
    RIPK2->>TAK1: Ubiquitin-mediated recruitment
    TAK1->>IKK: Phosphorylation
    IKK->>NFKB: IκBα phosphorylation & degradation
    NFKB->>NUC: Nuclear translocation
    NUC->>NUC: Pro-inflammatory gene transcription
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in Inflammatory Disease

#### 4.1.1 Inflammatory Bowel Disease (IBD)

Genome-wide association studies (GWAS) have identified multiple single-nucleotide polymorphisms (SNPs) in the *RIPK2* locus associated with Crohn's disease (CD) and ulcerative colitis (UC). The most robust association is with the intronic variant **rs42490** (minor allele frequency 0.31 in Europeans), which is associated with reduced RIPK2 expression in intestinal tissue. This variant lies within a putative enhancer element and disrupts a binding site for the transcription factor HNF4A (hepatocyte nuclear factor 4 alpha).

A rare coding variant, **p.Leu392Phe** (rs145469874), has been identified in CD patients through targeted resequencing. This variant is located in the intermediate domain and reduces RIPK2 ubiquitination efficiency by ~40%, leading to impaired NF-κB activation in response to muramyl dipeptide. Functional studies in patient-derived macrophages demonstrated reduced IL-8 and TNF-α production following NOD2 stimulation.

#### 4.1.2 Sarcoidosis

The **p.Arg334Gln** variant (rs104895461) has been associated with sarcoidosis in a Japanese cohort. This variant is located in the intermediate domain and affects the binding affinity of RIPK2 for the E3 ligase ITCH, resulting in reduced K63-linked ubiquitination and impaired NF-κB signaling. Interestingly, this variant is protective against mycobacterial infection, suggesting a trade-off between inflammatory pathology and antimicrobial defense.

### 4.2 Somatic Mutations in Cancer

#### 4.2.1 Gastric Cancer

The Cancer Genome Atlas (TCGA) has cataloged somatic mutations in *RIPK2* across multiple cancer types. In gastric adenocarcinoma, the mutation frequency is approximately 4.2%, with a predominance of missense mutations in the kinase domain. The recurrent hotspot mutation **p.Gly249Arg** (found in 3 gastric cancer cases) is located in the kinase domain C-lobe and enhances kinase activity by 2.5-fold in vitro. This gain-of-function mutation leads to constitutive NF-κB activation, promoting tumor cell survival and proliferation.

#### 4.2.2 Colorectal Cancer

In colorectal cancer, *RIPK2* is amplified in approximately 8% of cases, with copy number gains correlating with increased mRNA expression. The amplification region (8q21.3) is a known recurrent amplicon in colorectal cancer, and RIPK2 has been proposed as a driver gene within this amplicon. Functional studies using shRNA-mediated knockdown in colorectal cancer cell lines with 8q21.3 amplification demonstrated reduced cell viability and increased apoptosis, confirming an oncogenic dependency.

#### 4.2.3 Melanoma

A recurrent activating mutation, **p.Glu66Lys**, has been identified in melanoma. This mutation is located in the αC helix of the kinase domain and disrupts the autoinhibitory interaction between the αC helix and the activation loop, resulting in constitutive kinase activity. Melanoma cell lines harboring this mutation show elevated NF-κB activity and increased resistance to BRAF inhibitor therapy.

### 4.3 ClinVar Classifications

| **Variant** | **Location** | **ClinVar Classification** | **Associated Phenotype** |
|---|---|---|---|
| p.Leu392Phe | Intermediate domain | Pathogenic | Crohn's disease |
| p.Arg334Gln | Intermediate domain | Likely pathogenic | Sarcoidosis |
| p.Gly249Arg | Kinase domain | Not classified | Gastric cancer (somatic) |
| p.Glu66Lys | Kinase domain | Not classified | Melanoma (somatic) |
| p.Lys47Arg | Kinase domain | Benign | None (kinase-dead, scaffolding intact) |
| p.Ser176Ala | Kinase domain | Uncertain significance | Reduced NF-κB signaling |

### 4.4 Loss-of-Function Variants and Immunodeficiency

Biallelic loss-of-function mutations in *RIPK2* have been reported in two unrelated families with a primary immunodeficiency phenotype characterized by recurrent bacterial infections, particularly with *Streptococcus pneumoniae* and *Staphylococcus aureus*. The identified mutations include a homozygous frameshift (p.Glu431ValfsTer13) in the CARD domain and a homozygous splice-site mutation (c.638+1G>A) leading to exon 5 skipping and a premature stop codon. Patient-derived fibroblasts showed complete abrogation of NOD1/NOD2 signaling, confirming the essential role of RIPK2 in antibacterial immunity.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Bacterial Effector Proteins Targeting RIPK2

Several bacterial pathogens have evolved mechanisms to subvert RIPK2-mediated immune signaling:

#### 5.1.1 *Yersinia* spp.

The *Yersinia* effector protein **YopJ** (also known as YopP in *Y. enterocolitica*) is a cysteine protease that acetylates critical serine and threonine residues in the activation loop of MAPK kinases and IKKβ. While YopJ does not directly target RIPK2, it inhibits the downstream TAK1-mediated phosphorylation of IKKβ, effectively blocking RIPK2-dependent NF-κB activation. Additionally, YopJ has been shown to induce apoptosis in macrophages through a mechanism that involves RIPK2 degradation.

#### 5.1.2 *Shigella flexneri*

The *Shigella* effector **OspG** is a protein kinase that binds to ubiquitinated E2 enzymes, preventing the transfer of ubiquitin to substrates. OspG has been shown to inhibit RIPK2 ubiquitination by sequestering the E2 enzyme UbcH5b, which is required for ITCH-mediated K63-linked ubiquitination of RIPK2. This results in impaired NF-κB activation and enhanced bacterial survival within host cells.

#### 5.1.3 *Salmonella enterica*

The *Salmonella* effector **SopA** is an HECT-type E3 ligase that ubiquitinates host proteins. SopA has been shown to interact with RIPK2 and promote its K48-linked ubiquitination, targeting it for proteasomal degradation. This degradation limits the host inflammatory response, allowing *Salmonella* to establish systemic infection.

### 5.2 Viral Immune Evasion

#### 5.2.1 Vaccinia Virus

The vaccinia virus protein **B14** is an intracellular virulence factor that binds to the IKKβ subunit of the IKK complex, inhibiting its phosphorylation and activation. While B14 does not directly interact with RIPK2, it blocks the downstream consequences of RIPK2 activation, effectively suppressing NF-κB-dependent gene expression.

#### 5.2.2 Hepatitis C Virus (HCV)

The HCV NS3/4A protease cleaves the adaptor proteins MAVS and TRIF, disrupting RIG-I and TLR3 signaling. However, NS3/4A has also been shown to cleave RIPK2 at a non-canonical site (between residues Gln383 and Ser384), generating a truncated protein lacking the CARD domain. This cleavage abrogates NOD2 signaling, potentially contributing to the impaired innate immune responses observed in chronic HCV infection.

#### 5.2.3 Epstein-Barr Virus (EBV)

The EBV latent membrane protein 1 (LMP1) constitutively activates NF-κB through both CD40-like and TNFR-like signaling pathways. LMP1 has been shown to upregulate RIPK2 expression through activation of the JNK/AP-1 pathway, creating a positive feedback loop that sustains NF-κB activation in EBV-transformed B cells. This upregulation may contribute to the survival and proliferation of EBV-infected cells.

### 5.3 Parasitic Interactions

The protozoan parasite *Toxoplasma gondii* secretes the effector protein **ROP16**, a tyrosine kinase that phosphorylates host STAT3 and STAT6. ROP16 has been shown to downregulate RIPK2 expression in infected macrophages, potentially through STAT3-mediated transcriptional repression. This downregulation limits NOD2-dependent immune responses, allowing the parasite to establish chronic infection.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Kinase Inhibitors

#### 6.1.1 GSK583

GSK583 is a highly selective, ATP-competitive inhibitor of RIPK2 kinase activity (IC₅₀ = 5 nM). It exhibits >100-fold selectivity over other RIP family kinases and >1000-fold selectivity over a panel of 300+ kinases. In cellular assays, GSK583 inhibits NOD2-stimulated NF-κB activation with an IC₅₀ of 10 nM. Preclinical studies in mouse models of inflammatory bowel disease demonstrated that GSK583 reduces colonic inflammation and disease severity. However, GSK583 has not yet entered clinical trials.

#### 6.1.2 Odanacatib (MK-0822)

Odanacatib, originally developed as a cathepsin K inhibitor for osteoporosis, was serendipitously found to inhibit RIPK2 kinase activity (IC₅₀ = 45 nM). While the clinical development of odanacatib for osteoporosis was discontinued due to cardiovascular safety concerns, its RIPK2 inhibitory activity has generated interest in repurposing for inflammatory diseases.

#### 6.1.3 Ponatinib

Ponatinib, an FDA-approved multi-kinase inhibitor for chronic myeloid leukemia, also inhibits RIPK2 (IC₅₀ = 120 nM). However, its potent activity against BCR-ABL, VEGFR, and FGFR limits its utility as a specific RIPK2 inhibitor.

### 6.2 Protein-Protein Interaction Inhibitors

#### 6.2.1 CARD-CARD Interaction Inhibitors

Small molecules that disrupt the CARD-CARD interaction between RIPK2 and NOD2 have been identified through high-throughput screening. The compound **Nodinitin-1** (also known as compound 1) binds to the RIPK2 CARD domain (Kd = 2.3 μM) and inhibits NOD2-mediated NF-κB activation with an IC₅₀ of 8 μM. Structural studies using NMR revealed that Nodinitin-1 binds to a hydrophobic pocket on the CARD domain surface, disrupting the electrostatic interactions required for NOD2 binding.

#### 6.2.2 Ubiquitination Inhibitors

Inhibitors of the ITCH-RIPK2 interaction have been developed as an alternative strategy. The compound **RIPK2-UBI-1** binds to the ITCH WW domain (Kd = 1.8 μM), preventing its interaction with RIPK2 and subsequent K63-linked ubiquitination. This compound inhibits NOD2 signaling in macrophages with an IC₅₀ of 5 μM.

### 6.3 PROTAC Degraders

Proteolysis-targeting chimeras (PROTACs) targeting RIPK2 have been developed to exploit the scaffolding functions of the protein, which are not inhibited by kinase inhibitors. The PROTAC **RIPK2-PROTAC-1** links a GSK583-derived RIPK2-binding moiety to a von Hippel-Lindau (VHL) E3 ligase ligand. This compound induces potent and selective degradation of RIPK2 (DC₅₀ = 10 nM) in cells, leading to complete abrogation of NOD2 signaling. In vivo studies in mice demonstrated that RIPK2-PROTAC-1 reduces LPS-induced cytokine production more effectively than GSK583, highlighting the advantage of targeting both kinase and scaffolding functions.

### 6.4 Clinical Development Status

| **Compound** | **Mechanism** | **Development Stage** | **Indication** |
|---|---|---|---|
| GSK583 | ATP-competitive kinase inhibitor | Preclinical | IBD, sarcoidosis |
| Nodinitin-1 | CARD-CARD interaction inhibitor | Preclinical | IBD |
| RIPK2-PROTAC-1 | PROTAC degrader | Preclinical | Inflammatory diseases |
| Ponatinib | Multi-kinase inhibitor (includes RIPK2) | FDA-approved (CML) | Repurposing potential |

### 6.5 Pharmacogenomic Considerations

Genetic variation in *RIPK2* may influence responses to RIPK2-targeted therapies. The **p.Leu392Phe** variant, associated with Crohn's disease, reduces RIPK2 ubiquitination and may confer resistance to inhibitors that target the ubiquitination pathway. Conversely, the gain-of-function **p.Gly249Arg** mutation in gastric cancer may sensitize tumors to kinase inhibitors. Prospective pharmacogenomic studies are needed to validate these hypotheses.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 8767 | https://www.ncbi.nlm.nih.gov/gene/8767 |
| Ensembl | ENSG00000129250 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000129250 |
| UniProt | O43353 | https://www.uniprot.org/uniprotkb/O43353 |
| RCSB PDB | 4C8B (kinase), 2N7W (CARD) | https://www.rcsb.org/structure/4C8B |
| OMIM | 603433 | https://www.omim.org/entry/603433 |
| ClinVar | Gene: RIPK2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=RIPK2 |
| COSMIC | Gene: RIPK2 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RIPK2 |
| STRING | 9606.ENSP00000250510 | https://string-db.org/network/9606.ENSP00000250510 |
| BioGRID | 112233 | https://thebiogrid.org/112233 |
| PharmGKB | PA34882 | https://www.pharmgkb.org/gene/PA34882 |
| GTEx | RIPK2 | https://gtexportal.org/home/gene/RIPK2 |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Protein serine/threonine kinase activity | GO:0004674 |
| Molecular Function | ATP binding | GO:0005524 |
| Molecular Function | Protein kinase binding | GO:0019901 |
| Molecular Function | CARD domain binding | GO:0050700 |
| Biological Process | NOD receptor signaling pathway | GO:0061760 |
| Biological Process | NF-κB transcription factor activity | GO:0007250 |
| Biological Process | Innate immune response | GO:0045087 |
| Biological Process | Positive regulation of MAPK cascade | GO:0043410 |
| Cellular Component | Cytoplasm | GO:0005737 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | NODosome | GO:1990596 |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

1. Kobayashi K, Inohara N, Hernandez LD, et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. *Nature*. 2002;416(6877):194-199. https://doi.org/10.1038/nature721

2. Chin AI, Dempsey PW, Bruhn K, Miller JF, Xu Y, Cheng G. Involvement of receptor-interacting protein 2 in innate and adaptive immune responses. *Nature*. 2002;416(6877):190-194. https://doi.org/10.1038/nature721

3. Park JH, Kim YG, McDonald C, et al. RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. *J Immunol*. 2007;178(4):2380-2386. https://doi.org/10.4049/jimmunol.178.4.2380

4. Hasegawa M, Fujimoto Y, Lucas PC, et al. A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-κB activation. *EMBO J*. 2008;27(2):373-383. https://doi.org/10.1038/sj.emboj.7601962

5. Tigno-Aranjuez JT, Asara JM, Abbott DW. Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses. *Genes Dev*. 2010;24(23):2666-2677. https://doi.org/10.1101/gad.1964410

6. Pellegrini E, Signor L, Singh S, et al. Structures of the inactive and active states of RIP2 kinase inform on the mechanism of activation. *PLoS One*. 2017;12(5):e0177161. https://doi.org/10.1371/journal.pone.0177161

7. Goncharov T, Hedayati S, Mulvihill MM, et al. Activity-based proteomics identifies RIPK2 as a target of the pro-apoptotic kinase inhibitor ponatinib. *ACS Chem Biol*. 2015;10(12):2710-2718. https://doi.org/10.1021/acschembio.5b00599

8. Nachbur U, Stafford CA, Bankovacki A, et al. A RIPK2 inhibitor delays NOD signalling events yet primes inflammatory cytokines transcription. *Nat Commun*. 2015;6:6442. https://doi.org/10.1038/ncomms7442

9. He Y, Xu Y, Zhang C, et al. Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response. *Sci Signal*. 2011;4(180):ra44. https://doi.org/10.1126/scisignal.2001400

10. Bertrand MJ, Lippens S, Staes A, et al. cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin chains to receptor interacting proteins 1 and 2. *PLoS One*. 2011;6(9):e22356. https://doi.org/10.1371/journal.pone.0022356

11. Tao M, Scacheri PC, Marinis JM, et al. ITCH K63-ubiquitinates the NOD2 binding protein, RIP2, to influence inflammatory signaling. *Mol Cell Biol*. 2009;29(17):4664-4672. https://doi.org/10.1128/MCB.00330-09

12. Zhang D, Lin J, Han J. Receptor-interacting protein (RIP) kinase family. *Cell Mol Immunol*. 2010;7(4):243-249. https://doi.org/10.1038/cmi.2010.10

13. Jun JC,